BioCentury
ARTICLE | Clinical News

ARRY-614: Phase I data

January 13, 2014 8:00 AM UTC

The open-label, dose-escalation, U.S. Phase I ARRY-614-112 trial in 71 evaluable patients with low- to intermediate-1-risk MDS showed that oral ARRY-614 led to hematologic improvement according to 200...